相关实验视频

Updated: May 13, 2025

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue

Published on: May 8, 2018

神经缩因子α1基因治疗在阿尔茨海默氏症:范围和进展

Ammara Shaikh¹, Fairus Ahmad¹, Seong Lin Teoh¹

¹Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

Frontiers in molecular neuroscience

|April 16, 2025

概括

本综述探讨了神经营养因子α1 (NF-α1) 作为潜在的阿尔茨海默病 (AD) 治疗方法. NF-α1表现出神经保护性质,为AD治疗和管理提供了新的途径.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

阿尔茨海默病 (AD) 是痴呆的主要原因,其特点是粉样β和病理.
阿尔茨海默病涉及神经递质系统异常和降低神经营养因子,如BDNF和NGF.
目前对阿尔茨海默病变的理解需要探索新的治疗点.

研究的目的:

审查神经营养因子α1 (NF-α1) 在阿尔茨海默病中的新兴作用.
评估NF-α1对AD的神经保护性和神经发生促进性.
为了比较NF-α1基因疗法与现有的基于神经热素的AD治疗方法.

主要方法:

关于阿尔茨海默病和神经变因子研究的文献综述.
对神经元健康中的碳氧酶E (NF-α1) 功能研究的分析.
对AD的基因治疗方法的比较评估.

主要成果:

NF-α1表现出与AD相关的显著神经保护作用.
NF-α1促进神经发生,这是大脑修复的关键过程.
使用NF-α1的基因疗法是目前治疗方法的有希望的替代方案.

结论:

NF-α1是阿尔茨海默病的潜在治疗剂.
NF-α1基因疗法需要进一步研究AD的治疗.
针对神经营养因子提供了一种新的策略来对抗AD的进展.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.粉胺β的化物.碳氧胺酶E的使用.在AD中使用基因疗法.神经递质系统 (NTS) 异常神经营养因子α1 (NF-α1)

更多相关视频

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...